Virtual Network's Login.
About the Conference:
Following the success of the previous ESH CAR-T conferences, we are pleased to announce the 3rd How I Manage CAR-T Therapies and Bispecific Antibodies for my Patients.
CAR-T cells and bispecific antibodies have advanced our therapeutic armamentarium for haematological malignancies. The programme of this ESH conference aims to provide an overview of the benefits and risks of currently available therapies for acute lymphoblastic leukaemia, lymphoma and multiple myeloma. Special focus will be placed on the advantages and disadvantages of bispecific antibodies vs. cellular therapies (including T cells, NK cells and transplant strategies). Future perspectives regarding applications in other haematological malignancies will also be discussed.
The programme will include:
Keynote lectures - Case-based lectures
Interactive Case Presentations - Roundtables
Panel Discussions - Debates - Poster Walks
Meet the Expert Sessions - Voting technology
